Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics (NASDAQ: RNAC), a clinical-stage biotechnology company focused on mRNA cell therapies for autoimmune diseases, has granted inducement awards to three new employees. On January 2, 2025, the company issued options to purchase a total of 19,324 shares of common stock at an exercise price of $16.93 per share, matching the closing price on Nasdaq that day.
The options were granted under the company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and approved by the board. The vesting schedule includes 25% on January 2, 2026, followed by three equal annual installments until full vesting on January 2, 2029. The options have a ten-year term and were granted under Nasdaq Rule 5635(c)(4) as employment inducements.
Cartesian Therapeutics (NASDAQ: RNAC), un'azienda biotecnologica in fase clinica focalizzata sulle terapie cellulari mRNA per le malattie autoimmuni, ha concesso premi di incentivazione a tre nuovi dipendenti. Il 2 gennaio 2025, l'azienda ha emesso opzioni per acquistare un totale di 19.324 azioni ordinarie a un prezzo di esercizio di $16.93 per azione, corrispondente al prezzo di chiusura su Nasdaq quel giorno.
Le opzioni sono state concesse nell'ambito del Piano di Incentivazione per i Dipendenti del 2018 modificato e aggiornato e approvato dal consiglio. Il piano di vesting prevede il 25% il 2 gennaio 2026, seguito da tre rate annuali uguali fino al completo vesting il 2 gennaio 2029. Le opzioni hanno una durata di dieci anni e sono state concesse ai sensi della Regola 5635(c)(4) di Nasdaq come incentivi all'assunzione.
Cartesian Therapeutics (NASDAQ: RNAC), una empresa biotecnológica en etapa clínica enfocada en terapias celulares de ARNm para enfermedades autoinmunitarias, ha otorgado premios de inducimiento a tres nuevos empleados. El 2 de enero de 2025, la empresa emitió opciones para adquirir un total de 19,324 acciones comunes a un precio de ejercicio de $16.93 por acción, igualando el precio de cierre en Nasdaq ese día.
Las opciones se otorgaron bajo el Plan de Incentivos de Inducimiento de Empleo enmendado y restablecido de 2018 y fueron aprobadas por la junta. El calendario de adquisición incluye el 25% el 2 de enero de 2026, seguido de tres pagos anuales iguales hasta la adquisición completa el 2 de enero de 2029. Las opciones tienen un plazo de diez años y se otorgaron bajo la Regla 5635(c)(4) de Nasdaq como inducimientos laborales.
Cartesian Therapeutics (NASDAQ: RNAC)은 자가면역 질환에 대한 mRNA 세포 치료에 집중하는 임상 단계의 생명공학 회사로, 세 명의 신입 직원에게 유인 보상을 제공했습니다. 2025년 1월 2일, 회사는 19,324 주식의 보통주를 주당 $16.93의 행사 가격으로 구매할 수 있는 옵션을 발행했으며, 이는 그 날 Nasdaq의 종가와 일치합니다.
옵션은 회사의 개정 및 재확인된 2018 고용 유인 인센티브 수여 계획에 따라 부여되었으며, 이사회의 승인을 받았습니다. 귀속 일정은 2026년 1월 2일 25%를 포함하고, 이후 2029년 1월 2일까지 전액 귀속될 때까지 세 차례의 동일한 연간 분할 상환이 이어집니다. 옵션의 유효 기간은 10년이며, 고용 유인을 위한 Nasdaq 규칙 5635(c)(4)에 따라 부여되었습니다.
Cartesian Therapeutics (NASDAQ: RNAC), une entreprise biopharmaceutique en phase clinique spécialisée dans les thérapies cellulaires à base d'ARNm pour les maladies auto-immunes, a attribué des primes d'incitation à trois nouveaux employés. Le 2 janvier 2025, l'entreprise a émis des options pour acheter un total de 19 324 actions ordinaires à un prix d'exercice de $16.93 par action, correspondant au prix de clôture sur le Nasdaq ce jour-là.
Les options ont été accordées dans le cadre du Plan d'Incentive d'Induction de l'Emploi amendé et révisé de 2018 et ont été approuvées par le conseil d'administration. Le calendrier d'acquisition comprend 25 % le 2 janvier 2026, suivi de trois versements annuels égaux jusqu'à l'acquisition complète le 2 janvier 2029. Les options ont une durée de dix ans et ont été accordées conformément à la règle 5635(c)(4) de Nasdaq en tant qu'incitations à l'emploi.
Cartesian Therapeutics (NASDAQ: RNAC), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf mRNA-Zelltherapien zur Behandlung von Autoimmunerkrankungen konzentriert, hat drei neuen Mitarbeitern Anreize gewährt. Am 2. Januar 2025 gab das Unternehmen Optionen zur Kauf von insgesamt 19.324 Aktien zum Ausübungspreis von $16.93 pro Aktie aus, was dem Schlusskurs an der Nasdaq an diesem Tag entspricht.
Die Optionen wurden im Rahmen des geänderten und neu gefassten Incentive-Plans für Angehörige des Unternehmens aus dem Jahr 2018 gewährt und vom Vorstand genehmigt. Der Vesting-Zeitplan sieht 25 % am 2. Januar 2026 vor, gefolgt von drei gleichen jährlichen Raten bis zur vollständigen Vesting am 2. Januar 2029. Die Optionen haben eine Laufzeit von zehn Jahren und wurden gemäß der Nasdaq-Regel 5635(c)(4) als Anreize zur Einstellung gewährt.
- None.
- None.
FREDERICK, Md., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to three new employees. On January 2, 2025, the Company issued to these employees options to purchase an aggregate of 19,324 shares of the Company’s common stock with an exercise price of
About Cartesian Therapeutics
Cartesian Therapeutics is a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is an mRNA CAR-T in Phase 2b clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X, formerly known as Twitter.
Contact Information:
Investor Contact:
Megan LeDuc
Associate Director, Investor Relations
megan.leduc@cartesiantx.com
Media Contact:
David Rosen
Argot Partners
david.rosen@argotpartners.com
FAQ
What is the exercise price of RNAC's new stock options granted on January 2, 2025?
How many shares are covered by RNAC's January 2025 inducement stock options?
What is the vesting schedule for RNAC's January 2025 inducement stock options?
How long is the term of RNAC's January 2025 inducement stock options?
